PEG-uricase in the management of treatment-resistant gout and hyperuricemia.

[1]  M. Hershfield,et al.  Uricase and other novel agents for the management of patients with treatment-failure gout , 2007, Current rheumatology reports.

[2]  J. O'donnell,et al.  Emerging therapies in the long‐term management of hyperuricaemia and gout , 2007, Internal medicine journal.

[3]  M. Hershfield,et al.  Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. , 2007, Arthritis and rheumatism.

[4]  L. Kuller,et al.  Hyperuricemia and Incidence of Hypertension Among Men Without Metabolic Syndrome , 2007, Hypertension.

[5]  L. Burry,et al.  Clarifying the Role of Rasburicase in Tumor Lysis Syndrome , 2007, Pharmacotherapy.

[6]  J. Nolla,et al.  Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. , 2006, Arthritis and rheumatism.

[7]  T. Jansen,et al.  Rasburicase treatment in severe tophaceous gout: a novel therapeutic option , 2006, Clinical Rheumatology.

[8]  D. Furst,et al.  Gout and the risk of acute myocardial infarction. , 2006, Arthritis and rheumatism.

[9]  R. Terkeltaub,et al.  New developments in clinically relevant mechanisms and treatment of hyperuricemia , 2006, Current rheumatology reports.

[10]  G. Nuki,et al.  A concise history of gout and hyperuricemia and their treatment , 2006, Arthritis research & therapy.

[11]  시모나 멘데로비츠,et al.  A variant form of urate oxidase and use thereof , 2006 .

[12]  H. Schumacher,et al.  Serum Urate Levels and Gout Flares: Analysis From Managed Care Data , 2006, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[13]  M. Hershfield,et al.  Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase , 2005, Arthritis research & therapy.

[14]  M. Cairo,et al.  Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome. , 2005, Current pharmaceutical design.

[15]  J. A. Kruse,et al.  Hemolysis and Methemoglobinemia Secondary to Rasburicase Administration , 2005, The Annals of pharmacotherapy.

[16]  A. Gutiérrez-Macías,et al.  Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia , 2005, BMJ : British Medical Journal.

[17]  J. H. Acosta,et al.  Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? , 2005, Journal of the American Society of Nephrology : JASN.

[18]  H. Schumacher,et al.  Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. , 2005, Arthritis and rheumatism.

[19]  J. Hainsworth,et al.  Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Terkeltaub,et al.  Gout: on the brink of novel therapeutic options for an ancient disease. , 2004, Arthritis and rheumatism.

[21]  R. Wortmann,et al.  Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. , 2004, The Journal of rheumatology.

[22]  Mike A. Clark,et al.  Serum uric acid-lowering therapies: Where are we heading in management of hyperuricemia and the potential role of uricase , 2004, Current rheumatology reports.

[23]  R. Terkeltaub,et al.  The role of hypertension in cyclosporine-induced hyperuricemia , 2004, Current Rheumatology Reports.

[24]  G. Johnson,et al.  Applications of Magnetic Resonance Microscopy , 2004, Toxicologic pathology (Print).

[25]  S. Kong,et al.  A literature review of the epidemiology and treatment of acute gout. , 2003, Clinical therapeutics.

[26]  J. Nolla,et al.  Long-term efficacy of hyperuricaemia treatment in renal transplant patients. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  L. Truong,et al.  A role for uric acid in the progression of renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[28]  J. Bomalaski,et al.  Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. , 2002, The Journal of rheumatology.

[29]  F. Perez-Ruiz,et al.  Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. , 2002, Arthritis and rheumatism.

[30]  P. Caliceti,et al.  Immunological properties of uricase conjugated to neutral soluble polymers. , 2001, Bioconjugate chemistry.

[31]  M. Hershfield,et al.  Diabetes Insipidus in Uricase-deficient Mice: a Model for Evaluating Therapy with Poly(ethylene Glycol)-modified Uricase , 2000 .

[32]  D. Clive.  Renal transplant-associated hyperuricemia and gout. , 2000, Journal of the American Society of Nephrology : JASN.

[33]  P. Caliceti,et al.  Therapeutic proteins: a comparison of chemical and biological properties of uricase conjugated to linear or branched poly(ethylene glycol) and poly(N-acryloylmorpholine). , 2000, Farmaco.

[34]  M. Whitlow,et al.  Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. , 1999, Bioconjugate chemistry.

[35]  Y. G. Kim,et al.  Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[36]  L. Kwak,et al.  Conjugation of High-Molecular Weight Poly(ethylene glycol) to Cytokines: Granulocyte-Macrophage Colony-Stimulating Factors as Model Substrates , 1997 .

[37]  M. Relling,et al.  Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies , 1997, Leukemia.

[38]  T. Prangé,et al.  Crystal Structure of the protein drug urate oxidase-inhibitor complex at 2.05 Å resolution , 1997, Nature Structural Biology.

[39]  Samuel Zalipsky,et al.  Poly(ethylene glycol): Chemistry and Biological Applications , 1997 .

[40]  P. Caliceti,et al.  Branched and Linear Poly(Ethylene Glycol): Influence of the Polymer Structure on Enzymological, Pharmacokinetic, and Immunological Properties of Protein Conjugates , 1997 .

[41]  L. Kwak,et al.  Improved conjugation of cytokines using high molecular weight poly(ethylene glycol): PEG-GM-CSF as a prototype , 1997 .

[42]  R A Sayle,et al.  RASMOL: biomolecular graphics for all. , 1995, Trends in biochemical sciences.

[43]  B. Roche,et al.  Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases. , 1995, Revue du rhumatisme.

[44]  H. C. Hanger,et al.  Death following allopurinol hypersensitivity syndrome. , 1994, The New Zealand medical journal.

[45]  A. Bradley,et al.  Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[46]  G. Dollinger,et al.  On-line characterization of polyethylene glycol-modified proteins , 1991 .

[47]  Mark L. Greenberg,et al.  Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. , 1988, Annals of internal medicine.

[48]  F. Veronese,et al.  Surface modification of proteins activation of monomethoxy-polyethylene glycols by phenylchloroformates and modification of ribonuclease and superoxide dismutase , 1985, Applied biochemistry and biotechnology.

[49]  N. Kamatani,et al.  Hypouricaemic effect after oral administration in chickens of polyethylene glycol‐modified uricase entrapped in liposomes , 1984, The Journal of pharmacy and pharmacology.

[50]  D. Pennell,et al.  FATAL STEVENS-JOHNSON SYNDROME IN A PATIENT ON CAPTOPRIL AND ALLOPURINOL , 1984, The Lancet.

[51]  A. Rywlin,et al.  Woringer-Kolopp disease (pagetoid reticulosis). , 1983, The American Journal of dermatopathology.

[52]  F. Davis,et al.  Reduction of plasma urate levels in the cockerel with polyethylene glycol-uricase. , 1981, The Journal of pharmacology and experimental therapeutics.

[53]  F. Davis,et al.  Properties of two urate oxidases modified by the covalent attachment of poly(ethylene glycol). , 1981, Biochimica et biophysica acta.

[54]  F. Davis,et al.  HYPOURICAEMIC EFFECT OF POLYETHYLENEGLYCOL MODIFIED URATE OXIDASE , 1981, The Lancet.

[55]  D. Mitchison,et al.  FALSE-POSITIVE ACID-FAST SMEARS , 1975, The Lancet.

[56]  A. Prasad,et al.  Letter: Zinc deficiency in man. , 1974 .

[57]  G. Hitchings,et al.  Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. , 1966, Biochemical pharmacology.

[58]  P. Hudson,et al.  Uricolytic activity of purified uricase in two human beings. , 1957, Science.

[59]  H. Mahler,et al.  Studies on uricase. I. Preparation, purification, and properties of a cuproprotein. , 1955, The Journal of biological chemistry.

[60]  PEG-URATE OXIDASE CONJUGATES AND USE THEREOF PEG-URICASE KONJUGATE UND VERWENDUNG DAVON CONJUGUES PEG-URATE OXYDASE ET UTILISATION ASSOCIEE , 2005 .

[61]  C. Pui,et al.  Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome. , 2005, Contributions to nephrology.

[62]  M. Cairo,et al.  Tumor lysis syndrome: pathophysiology, definition, and alternative treatment approaches. , 2005, Clinical advances in hematology & oncology : H&O.

[63]  C. Pui,et al.  Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial , 2005, Leukemia.

[64]  D. Muzny,et al.  Two independent mutational events in the loss of urate oxidase during hominoid evolution , 2004, Journal of Molecular Evolution.

[65]  N. Schlesinger.  Management of acute and chronic gouty arthritis: present state-of-the-art. , 2004, Drugs.

[66]  M. Wilchek,et al.  A Simple and Efficient Method for Preparation of Monomethoxypolyethylene Glycol Activated with p-Nitrophenylchloroformate and Its Application to Modification of L-Asparaginase , 1996 .

[67]  J. Bonny.  [Applications of magnetic resonance imaging]. , 1989, Journal of cardiology. Supplement.

[68]  M. Wilchek,et al.  Immobilization of proteins and ligands using chlorocarbonates. , 1987, Methods in Enzymology.

[69]  M. Wilchek,et al.  [5] Immobilization of proteins and ligands using chlorocarbonates , 1987 .

[70]  I. Yamamoto,et al.  Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase. , 1985, International journal of immunopharmacology.

[71]  K. Hande,et al.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. , 1984, The American journal of medicine.

[72]  Y. Inada,et al.  Improved modification of yeast uricase with polyethylene glycol, accompanied with nonimmunoreactivity towards anti-uricase serum and high enzymic activity. , 1981, Enzyme.

[73]  Y. Ashihara,et al.  Modification of yeast uricase with polyethylene glycol: disappearance of binding ability towards anti-uricase serum. , 1979, Enzyme.

[74]  H. Doring,et al.  Surface Modification of Proteins , 1978 .

[75]  Rw Rundres.  Effects of a xanthine oxidase inhibitor on thiopurine metabolism, hyperuricemia and gout , 1963 .

[76]  E. Leone.  [Studies on uricase]. , 1955, Archivio di scienze biologiche.

[77]  G GUIMARAES,et al.  Essential hypertension , 1950, Revue de medecine aeronautique.